Bayer trumpets $1bn CRISPR deal with Mammoth Bio
pharmaphorum
JANUARY 10, 2022
Bayer has bolstered its cell and gene therapy platform by securing access to a CRISPR-based gene-editing platform developed by US biotech Mammoth Biosciences. The post Bayer trumpets $1bn CRISPR deal with Mammoth Bio appeared first on.
Let's personalize your content